Antibody-mediated LOX-1 inhibition in patients with residual inflammation after myocardial infarction: a randomized phase 2 trial

作者：Michelle L. O’Donoghue, David A. Morrow, Andrea L. Vavere, Dimitris Kardassis, Filipe A. Moura, Antônio Fagundes, Diego Ardissino, V. Bláha, Michael E. Farkouh, Eri Kato, Takeshi Kimura, Róbert Kiss, Ton Oude Ophuis, Joseph B. Selvanayagam, José López-Sendón, Wojciech Wojakowski, Azfar Zaman, João A.C. Lima, Michael T. Lu, Borek Foldyna, Julia Kuder, Jeong‐Gun Park, Sabina A. Murphy, Michelle Turton, Anna Collén, Anders Gabrielsen, Richard T. De George, Marc S. Sabatine, On behalf of the GOLDILOX-TIMI 69 Trial Investigators · 发表于：Nature Medicine · 年份：2025 · DOI：10.1038/s41591-025-03951-w · 被引用次数：8 · 研究领域：Atherosclerosis and Cardiovascular Diseases、Neutrophil, Myeloperoxidase and Oxidative Mechanisms、Microbial Metabolism and Applications